CannBioRx Life Sciences Corp
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $250.78 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
CannBioRx Life Sciences Corp had its IPO on 2017-06-27 under the ticker symbol ATNFW.
The company operates in the sector and industry. CannBioRx Life Sciences Corp has a staff strength of 0 employees.
Shares of CannBioRx Life Sciences Corp opened at $0.03 at the start of the last trading session i.e. 2023-03-21.
The stocks traded within a range of $0.02 - $0.03, and closed at $0.03.
This is a -10.88% slip from the previous day's closing price.
A total volume of 108,495 shares were traded at the close of the day’s session.
In the last one week, shares of CannBioRx Life Sciences Corp have slipped by -15.48%.
CannBioRx Life Sciences Corp's Key Ratios
CannBioRx Life Sciences Corp has a market cap of $250.78 million, indicating a price to book ratio of 0 and a price to sales ratio of 0.
In the last 12-months CannBioRx Life Sciences Corp’s revenue was $0 with a gross profit of $0 and an EBITDA of $-20990946. The EBITDA ratio measures CannBioRx Life Sciences Corp's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, CannBioRx Life Sciences Corp’s operating margin was 0% while its return on assets stood at -42.24% with a return of equity of -3754.4%.
In Q3, CannBioRx Life Sciences Corp’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
CannBioRx Life Sciences Corp’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $0 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into CannBioRx Life Sciences Corp’s profitability.
CannBioRx Life Sciences Corp stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 0.
CannBioRx Life Sciences Corp stock pays annual dividends of $ per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $34.34 million
- Total Liabilities
- $4.72 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
CannBioRx Life Sciences Corp ended 2023 with $34.34 million in total assets and $0 in total liabilities. Its intangible assets were valued at $34.34 million while shareholder equity stood at $26.08 million.
CannBioRx Life Sciences Corp ended 2023 with $3.50 million in deferred long-term liabilities, $4.72 million in other current liabilities, 3924.00 in common stock, $-85666267.00 in retained earnings and $13.97 million in goodwill. Its cash balance stood at $3.59 million and cash and short-term investments were $3.59 million. The company’s total short-term debt was $406,450 while long-term debt stood at $31522.00.
CannBioRx Life Sciences Corp’s total current assets stands at $6.51 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $2.51 million compared to accounts payable of $1.02 million and inventory worth $0.
In 2023, CannBioRx Life Sciences Corp's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, CannBioRx Life Sciences Corp paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
CannBioRx Life Sciences Corp stock is currently trading at $0.03 per share. It touched a 52-week high of $0.6298 and a 52-week low of $0.6298. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $0.04 and 200-day moving average was $0.09 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About CannBioRx Life Sciences Corp
180 Life Sciences Corp., a clinical-stage biotechnology company, focuses on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis, and pain. Its primary platform is a novel program to treat fibrosis and inflammation using anti-TNF, with its lead program in phase 2b/3 clinical trial. The company is headquatered in Menlo Park, California.